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Background/Aims:  Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable 
hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in 
patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC 
and conventional TACE using doxorubicin for advanced HCC. Methods: The high-dose HAIC group comprised 36 patients who 
were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main portal vein invasion 
(including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, 
radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 
5-fluorouracil (500 mg/m
2 on days 1~3) and cisplatin (60 mg/m
2 on day 2 every 4 weeks) via an implantable port system. In the 
TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a 
single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Results: Overall, 6 patients (8.9%) 
achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial 
response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival 
was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no 
serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group.  
Conclusions: High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE 
using doxorubicin in patients with intractable, advanced HCC. (Korean J Hepatol 2010;16:355-361)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most common 
cause of cancer death worldwide.
1 While treatment options 
including surgical resection, transplantation, and ablation can 
increase the chance of achieving complete remission, these 
strategies are not suitable for most HCC patients due to 
underlying cirrhosis or the advanced stage of the disease at the 
time of diagnosis. Still, many patients are diagnosed at an 
unresectable, advanced stage, though diagnosis of HCC at an 
early stage has been increased by virtue of surveillance of 
populations at high risk for the development of HCC.
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prognosis of patients with unresectable HCC is poor; if left 
untreated, the median survival is less than 6 months.
3,4 
Transarterial chemotherapy with or without embolization is 
widely used as a palliative therapy for unresectable, advanced 
HCC. Few studies have reported on patients with massive HCC 
(i.e., >10 cm in diameter); most reports on the treatment response 
of unresectable, advanced HCC have analyzed tumors 5~7 cm in 
size.
5,6 Currently, repetitive hepatic arterial infusion chemotherapy 
(HAIC) with chemotherapeutic agents delivered via an 
implantable port system has been reported to be a beneficial 
therapeutic option for patients with advanced HCC.
7-12 Woo 
et al. reported that both high-dose and low-dose HAIC regimens 
were effective and safe, and high-dose HAIC manifested a better 
tumor response and a tendency to improve survival compared to 
low-dose HAIC in a multicenter, prospective clinical trial 
conducted with intractable, advanced HCC patients with main 
portal vein invasion or bilobar involvement.
13 However, the 
comparative efficacy and safety of high-dose HAIC and 
transarterial chemoembolization (TACE) using doxorubicin, 
which is generally used as a palliative treatment, is unclear. The 
present study was undertaken to compare these regimens in 
terms of tumor response, survival and adverse effects in 
intractable, advanced HCC.
METHODS
Patients
In the HAIC group, patients with intractable, advanced HCC 
including major portal vein invasion or bilobar involvement 
were enrolled in a multicenter, prospective study from January 
2006 to January 2008, with the intent of evaluating efficacy and 
safety.
13 In the TACE group, data were retrospectively collected 
from patients in a single center meeting the same inclusion 
criteria between January 2003 and December 2007. The 
diagnosis of HCC was made either histologically or by typical 
radiologic findings of HCC on two dynamic imaging examinations, 
or based upon one dynamic technique with an elevated serum 
alpha-fetoprotein (AFP) levels (> 400 ng/mL). Intractable, 
advanced HCC was defined as HCC with main portal invasion, 
diffuse bilobar involvement and/or refractory to surgical resection 
or nonsurgical intervention [TACE, radiofrequency (RF) ablation, 
or percutaneous ethanol injection (PEI)].
11
Patients with HCC who met the following criteria were 
eligible for enrollment: age between 18 and 70 years, Child-Pugh 
score of 5 or 6, Eastern Cooperative Oncology Group (ECOG) 
performance status of 0~1, serum creatinine level ≤1.5 mg/dL, 
aminotransferase < 200 IU/mL, absolute neutrophil count ≥
1,500/mm
3, platelet count ≥75,000/mm
3 and hemoglobin ≥10 
g/dL. Patients were excluded if they had extrahepatic primary 
malignancy or metastasis and/or intractable comorbid medical 
illness. Informed consent was give to all patients. The prospective 
study was conducted according to the current declaration of 
Helsinki, and both prospective and retrospective studies were 
approved by the institutional ethics committee of each 
participating institution. 
Treatment methods
In the HAIC group, the regimen consisted of 5-fluorouracil 
(5-FU; 500 mg/m
2) for 5 hours on days 1~3 and cisplatin (60 
mg/m
2) for 2 hours on day 2. Each session was conducted every 4 
weeks via an implantable port system. In the TACE group, 
patients underwent a transarterial infusion of doxorubicin (10~60 
mg) in a mixture of 5~10 mL of lipiodol (Guerbet, Anulnay- 
sous-Boid, France), and was partly accompanied by embolization 
using gelfoam in selected cases. Unless contraindicated, 
treatment sessions were repeated every 4~8 weeks.
Intravenous hydration was carried to prevent nephrotoxicity 
and prophylactic anti-emetics comprised of 5-hydroxytryptamine-3 
antagonists were given to all patients in both groups. Treatment 
cycles were repeated until disease progressed or unacceptable 
toxicity was evident, or the patient refused treatment. The dose of 
chemotherapy or interval of treatment cycles was adjusted 
according to hepatic dysfunction or other significant toxicity at 
every treatment cycle. 
Study assessment
The primary efficacy was objective response rate [complete 
response (CR)+partial response (PR)] and the secondary efficacy 
was overall survival (OS). Pretreatment evaluation included 
medical history, physical examination, laboratory tests (complete 
blood count, blood chemistry, virus serology, serum AFP), chest 
and abdominal X-rays, and computed tomography (CT) or 
magnetic resonance imaging (MRI). During treatment, toxicity 
evaluation, laboratory tests, chest and abdominal X-rays were 
carried out repeatedly before each treatment cycle. CT scans 
were performed every two cycles or to evaluate tumor response 
or document disease progression. 
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Table 1. Baseline characteristics of the patients in the two groups
TACE group
(n=31)
HAIC group
(n=36)
P-value
Age (years)
* 55±9.2 (36~69) 53±10.9 (30~69) 0.562
‡
Causes HBV/HCV/non-viral 26/1/4 30/3/3 0.698
§
Stage UICC (III/IVA) 12/19 5/31 0.026
§
Tumor size (cm)
* 13.8±4 (10~26) 12±4 (5.5~24.8) 0.137
‡
AFP level (ng/ml)
† 1750 (3.12~195000) 1561 (3.2~155800) 0.110
‡
Child-Pugh class A/B 20/11 33/3 0.014
§
Antiviral treatment 
  Yes/No 2/29 13/23 0.007
§
Treatment number
* 1.7±1.4 (1~8) 3.4±2.3 (1~11) 0.000
‡
* Expressed as mean±SD (range), 
† Expressed as median (range), 
‡ Mann-Whitney U test, 
§ Fisher’s exact test.
TACE, Transarterial chemoembolization; HAIC, Hepatic arterial infusion chemotherapy; HBV, hepatitis B virus; HCV, hepatitis C 
virus; UICC, Union for International Cancer Control; AFP, alpha fetoprotein.
Health Organization criteria with the European Association for 
the Study of the Liver modifications. The objective response was 
defined as the sum of the CR and PR. Patients who achieved CR, 
PR, and stable disease (SD) were included in disease control 
group.
14 OS was calculated as the time from initiation of treatment 
until death or last follow-up visit. Toxicity was assessed 
according to the National Cancer Institute Common Toxicity 
Criteria (NCI-CTCAE; ver. 3.0).
15
Statistical analyses
Treatment response in both groups was analyzed using the 
Chi-square test or Fisher’s exact test. The chi-square test or 
Fisher’s exact test, where appropriate, and the Mann-Whitney 
U test were used for the analysis of other variables. The 
cumulative survival rates were estimated using the Kaplan-Meier 
method, and the differences were compared using the log-rank 
test. A Cox proportional-hazards model was used to identify 
independent predictors of survival. A P-value less than 0.05 was 
considered significant. All data was analyzed using SPSS 
version 14.0 software (SPSS, Chicago, IL, USA).
RESULTS
Patient characteristics
A total of 67 patients were analyzed. Of these, 31 patients 
were included in the TACE group, and 36 in the HAIC group. 
The baseline characteristics of the patients between two groups 
are summarized in Table 1. There was no significant difference 
between the two groups in terms of age, cause of HCC, tumor 
size and serum AFP. Patients with stage IVa, antiviral therapy, 
and multiple treatment cycles were more common in the HAIC 
group, while patients with Child-Pugh 7 were more common in 
TACE group. 
Treatment response
The median dose of cisplatin and 5-FU at each cycle was 100 
mg (range 60~120 mg) and 880 mg (range 500~1,000 mg) in the 
HAIC group. The median dose of doxorubicin at each cycle was 
45 mg (range 10~60 mg) in the TACE group. In the TACE group, 
5 out of 19 patients with stage IVa had main portal vein 
invasion, and embolization was not performed in these patients 
except for one patient, whom embolization of arterial branches 
was carried out. Evaluation of tumor response was possible in 61 
out of 67 patients, the remaining six patients were withdrawn 
from the study due to loss to follow-up or transfer to another 
hospital. There was no CR in both groups. PR, SD, and progressive 
disease (PD) were 16.7%, 33.3%, and 44.4%, respectively, in the 
HAIC group and 0%, 25.8%, and 61.2%, respectively, in the 
TACE group. The objective response rate (CR+PR) of the HAIC 
group was significantly higher (16.7%) than that of the TACE 
group (0%) (P=0.030). The disease control rate (CR+PR+SD) 
was also better in the HAIC group (50%) than in the TACE 
group (25.8%) (P=0.033) (Table 2).358  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Figure 1. Cumulative survival curves of the high-dose hepatic 
arterial infusion chemotherapy (HAIC) group (dashed line) and 
the conventional transarterial chemoembolization (TACE) group 
(solid line). Overall survival was significantly longer in the 
high-dose HAIC group than in the conventional TACE group 
(median survival, 193 vs. 119  days; log-rank test, P=0.026).
Table 2. Tumor response according to the treatment modality
Tumor response
TACE group
(n=31)
HAIC group
(n=36)
P-value
*
CR 0 0
PR 0  6 (16.7%) 0.030
SD  8 (25.8%) 12 (33.3%)
PD 19 (61.2%) 16 (44.4%)
* Fisher’s exact test.
TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; CR, complete response; PR, partial response; 
SD, stable disease; PD, progressive disease.
Survival and prognostic factors
Median follow-up period was 125.5 days (range, 9~716 days). 
The median OS of 193 days (95% CI 133~252 days) in the HAIC 
group was longer than that of 119 days (95% CI 41.9~196 days) 
in the TACE group (P=0.026) (Fig. 1). Univariate analysis 
identified prognostic factors related to survival: age (P =0.037), 
Child-Pugh class (P=0.040), treatment group (P=0.026), and 
number of treatments (P=0.003). Of these, no factor was 
revealed as an independent factor for survival on multivariate 
analysis (Table 3). 
Adverse events
Fever, abdominal discomfort, and nausea were common. 
Gastrointestinal/hepatic symptoms and neutropenia/throm-
bocytopenia were the most serious. Neutropenia and 
thrombocytopenia were more common in the HAIC group, while 
the frequency of hepatitis and hyperbilirubinemia was 
significantly higher in the TACE group (Table 4). Most adverse 
events were controlled by medical treatment or dose 
modification of chemotherapeutic agents. However, four patients 
in the HAIC group and 18 in the TACE group had stopped further 
treatments due to progressive deterioration of liver function.
DISCUSSION
The treatment strategies for patients with intractable, 
advanced HCC including main portal vein invasion, diffuse 
bilobar involvement, or progressive tumor refractory to surgical 
resection or nonsurgical intervention are very limited. When 
hepatic function is preserved, conventional TACE using 
doxorubicin is commonly used as a palliative treatment for 
patients with unresectable, advanced HCC.
6,16 Recently, HAIC 
using an implantable port system has been reported to be a useful 
palliative treatment for patients with advanced HCC.
7-12 The 
present study was conducted to compare the efficacy and safety 
of high dose HAIC, which showed favorable tumor response and 
survival with that of conventional TACE that is widely used 
palliatively. In the HAIC group, the objective response rate 
(CR+PR) was significantly improved compared to the TACE 
group (16.7% vs. 0%, P= 0.030), and median OS was also longer 
than in the TACE group (193 days vs. 119 days, P=0.026). 
Combination of two relatively high dose chemotherapeutic 
agents showed favorable results compared to chemotherapy with 
monoagent. 
While earlier studies analyzed patients with HCC of size less 
than 10 cm and no portal vein invasion, this study included 
patients with advanced HCC of modified UICC stage III or IVa, 
larger than 10 cm, infiltrative type and/or portal vein invasion. In 
HAIC
TACE
P=0.026
Time (years)Hee Yeon Kim, et al. A comparative study of hepatic arterial infusion chemotherapy and TACE  359
Table 3. Univariate and multivariate analyses of predictive factors for overall survival
Variables Number
Median
survival time
P-value
* Hazard ratio
(95% CI)
P-value
†
Age 
  ≤55 years
  >55 years
37
29
153
199
0.037 0.605
(0.293~1.249)
0.174
Causes
  v i r a l
  non-viral
59
7
155
100
0.801
UICC Stage
  III
  I V A
17
49
122
158
0.372 0.832
(0.410~1.686)
0.609
Tumor size
  ≤10 cm
  > 1 0  c m
17
49
155
154
0.432
AFP level
  ≤400 ng/mL
  >400 ng/mL
25
41
180
140
0.238
Child-Pugh class 
  A
  B
53
13
158
87
0.040 1.580
(0.647~3.861)
0.315
Antiviral treatment
  Y e s
  N o
15
51
464
154
0.052 2.407
(0.917~6.318)
0.074
Treatment group
  H A I C  g r o u p
  TACE group
36
31
193
119
0.026 1.059
(0.476~2.354)
0.888
Treatment number
  ≤2
  > 3
44
22
119
333
0.003 0.845
(0.377~1.894)
0.070
* Log-rank test, 
† Cox proportional hazard analysis.
CI, Confidence interval; UICC, Union for International Cancer Control, AFP; alpha fetoprotein, HAIC; hepatic arterial infusion chemotherapy,
TACE; transarterial chemoembolization.
the TACE group, embolization was not performed in 5 out of 19 
patients with stage IVa due to main portal vein invasion. 
Therefore, treatment response and OS of the TACE group in this 
study were poorer than in previous reports.
6,17 In the TACE 
group, only single session of TACE was performed in 18 patients 
as a result of hepatic dysfunction as the consequence of disease 
progression (8 patients) or toxicity due to chemotherapeutic 
agents (10 patients). This might lower the effectiveness of the 
TACE. Moreover, the prognosis is poor in hepatitis B virus 
(HBV)-associated HCC.
18 HBV, the major cause of HCC in this 
study, might contribute to the poor OS than previously 
reported. 
6,18 
Concerning adverse events, neutropenia and thrombocy-
topenia were more likely to occur in the HAIC group, although 
their occurrence was not statistically significant. A possible 
explanation is toxicity of chemotherapeutic agents as a 
consequence of frequent treatment cycle (4 weeks) and more 
treatments in the HAIC group. Hepatitis and hyperbilirubinemia 
were significantly frequent in the TACE group of patients. 
Tumor progression in the HAIC group was less common than in 
the TACE group owing to a greater number of treatments, 
absence of embolization and good treatment response. Furthermore, 
high-dose chemotherapeutic agents are given over 3 days, therefore, 
patients might tolerate the treatment with little hepatic toxicity, 
making more treatments possible.
The limitation of the current study is that a randomized and 
prospective comparison was not made. Therefore, the disparity 
in terms of tumor stage, antiviral treatments, and Child-Pugh 
class was apparent between the two groups. However, these 
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Table 4. Adverse events in each treatment group
TACE group
(n=31)
HAIC group
(n=36)
P-value
*
Anemia
(Hemoglobin <10 g/dL)
1 (3.2%) 2 (5.5%) 0.974
Neutropenia 
(ANC <1,500/mm
3)
2 (6.4%) 5 (13.8%) 0.057
Thrombocytopenia 
(Platelet <75,000/mm
3)
2 (6.4%) 4 (11.1%) 0.064
Hepatitis 
(ALT >2.5×UNL)
12 (38.7%) 6 (16.7%) 0.021
Hyperbilirubinemia 
(Total bilirubin >1.5×UNL)
12 (38.7%) 7 (19.4%) 0.035
Gastrointestinal toxicity 
(over Grade I)
7 (22.5%) 9 (25%) 0.765
Nephrotoxicity
(Creatinine >1.5×UNL)
00
* χ
2 or Fisher’s exact test.
TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; ANC, absolute neutrophil count; ALT, alanine 
transaminase; UNL, upper normal limit.
analysis. Even if the treatment response and OS were favorable 
in the HAIC group on the univariate analysis, treatment group 
was not an independent predictive factor for OS. This might be 
caused by the baseline distinction between two groups. However, 
it is meaningful that treatment response in the HAIC group was 
better than the TACE group in spite of more patients with 
advanced stage while preserved hepatic function and antiviral 
treatments. 
To date, there are no standard guidelines for treatment of 
intractable, advanced HCC, although various therapeutic 
approaches for these patients have been attempted. In 
conclusion, high dose HAIC might be effective and safe compared 
to conventional TACE using doxorubicin in intractable, 
advanced HCC, and has a potential to improve survival outcome. 
Further prospective, comparative randomized controlled trials 
are needed to confirm the beneficial effect of high dose HAIC in 
intractable, advanced HCC. 
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